<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01724918</url>
  </required_header>
  <id_info>
    <org_study_id>LIVE 001</org_study_id>
    <nct_id>NCT01724918</nct_id>
  </id_info>
  <brief_title>Lacosamide IV and EEG/EKG (LIVE) Study</brief_title>
  <acronym>LIVE</acronym>
  <official_title>Lacosamide IV and EEG/EKG (LIVE) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lawson Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UCB Pharma GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Lawson Health Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of different intravenous doses (IV) of a&#xD;
      new anti-epileptic drug (AED) called lacosamide on continuous EEG (electroencephalogram)&#xD;
      rhythms (or brain rhythms) in subjects with focal seizures and the tolerability of those&#xD;
      doses by patients. In addition, this study will assess the effect of IV lacosamide on EKG&#xD;
      (electrocardiogram), a test which checks for problems with the electrical activity of the&#xD;
      heart.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The impact of antiepileptic drugs on the EEG can vary from marked to none. A small number of&#xD;
      AEDs also affect the EKG. Lacosamide is a new AED that selectively enhances slow inactivation&#xD;
      of voltage-gated sodium channels, resulting in stabilization of hyperexcitable neuronal&#xD;
      membranes and inhibition of repetitive neuronal firing. Information is lacking about the&#xD;
      effect of lacosamide on brain and heart rhythms.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Time limitation for recruitment exceeded. 72 of 90 estimated sample recruited.&#xD;
  </why_stopped>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the number of interictal spikes</measure>
    <time_frame>One hour before and after drug</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in frequency and quantity of background EEG rhythms</measure>
    <time_frame>One hour before and after drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in EKG (QT, PR interval and heart rhythm)</measure>
    <time_frame>One hour before and after drug</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>Up to 4 hours after start of infusion</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Focal Epilepsy</condition>
  <arm_group>
    <arm_group_label>100 mg IV</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>100 mg IV lacosamide infused over 30 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>200 mg IV</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>200 mg IV lacosamide infused over 30 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>400 mg IV</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>400 mg IV lacosamide infused over 30 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lacosamide</intervention_name>
    <arm_group_label>100 mg IV</arm_group_label>
    <arm_group_label>200 mg IV</arm_group_label>
    <arm_group_label>400 mg IV</arm_group_label>
    <other_name>Vimpat</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is informed and given ample time and opportunity to think about her/his&#xD;
             participation and has given her/his written informed consent.&#xD;
&#xD;
          2. Adult patients 18-65 years&#xD;
&#xD;
          3. Diagnosis of focal epilepsy&#xD;
&#xD;
          4. Continuous EEG and video monitoring&#xD;
&#xD;
          5. Continuous EKG&#xD;
&#xD;
          6. Active EEG showing frequent spikes, electrographic or clinical seizures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject has no IV access.&#xD;
&#xD;
          2. Subject is hemodynamically unstable.&#xD;
&#xD;
          3. Previous use of Lacosamide&#xD;
&#xD;
          4. Primary generalized epilepsy&#xD;
&#xD;
          5. Non-epileptic seizures&#xD;
&#xD;
          6. No significant cardiac, renal or hepatic disease&#xD;
&#xD;
          7. No cardiac arrhythmias including heart block&#xD;
&#xD;
          8. Subject is a pregnant or lactating woman.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard McLachlan, MD, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>London Health Sciences Centre, University Campus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Foothills Medical Center</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Western Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal University Hospital</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 0W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>October 31, 2012</study_first_submitted>
  <study_first_submitted_qc>November 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 12, 2012</study_first_posted>
  <last_update_submitted>September 23, 2016</last_update_submitted>
  <last_update_submitted_qc>September 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lawson Health Research Institute</investigator_affiliation>
    <investigator_full_name>Rick McLachlan</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>IV lacosamide</keyword>
  <keyword>focal epilepsy</keyword>
  <keyword>EEG</keyword>
  <keyword>EKG</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Epilepsies, Partial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lacosamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

